- Home
- DSGN
as 12-20-2024 4:00pm EST
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 353.9M | IPO Year: | 2021 |
| Target Price: | $7.00 | AVG Volume (30 days): | 208.4K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.25 - $7.77 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Design Therapeutics Inc. (DSGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Prasad Deepa | DSGN | Director | Dec 18 '24 | Sell | $6.27 | 3,806 | $23,863.62 | 20,000 |
Latest Design Therapeutics Inc. News
DSGN Breaking Stock News: Dive into DSGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
GlobeNewswire
a month ago
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
Simply Wall St.
2 months ago
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
Simply Wall St.
3 months ago
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock
GlobeNewswire
3 months ago
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Zacks
4 months ago
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
Simply Wall St.
4 months ago
With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors
GlobeNewswire
5 months ago
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
Compare DSGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DSGN Design Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.